Nonpeptide corticotropin releasing hormone type 1 receptor antagonists as medications and imaging agents

Drugs of the Future

Volumn 27, Issue 11, 2002, Pages 1093-1100

  Contoreggi, Carlo ^a   Ayala, Alejandro ^a   Grant, Steven ^a   Eckelman, William ^a   Webster, Elizabeth ^a   Rice, Kenner ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTALARMIN; BROMINE 77; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CARBON 11; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR TYPE 1; FLUORINE 18; GLUCOCORTICOID; HYDROCORTISONE; LIGAND; MEMBRANE RECEPTOR; NEUROTRANSMITTER; SAUVAGINE; STEROID HORMONE; STRESSCOPIN RELATED PEPTIDE; UNCLASSIFIED DRUG; UROCORTIN; UROCORTIN III; UROTENSIN I;

ADRENAL GLAND; ALCOHOL ABUSE; ANXIETY DISORDER; DEPRESSION; DIAGNOSTIC IMAGING; EATING DISORDER; ENDOCRINE SYSTEM; HORMONE RECEPTOR INTERACTION; HYDROCORTISONE RELEASE; HYPOPHYSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ISOTOPE LABELING; MENTAL DISEASE; MOLECULAR DYNAMICS; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RECEPTOR AFFINITY; RECEPTOR DENSITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS; SUBSTANCE ABUSE;

EID: 0036878411     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.11.857018     Document Type: Review

References (39)

1. Chrousos, G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995, 332: 1351-62.
2. Eckart, K., Radulovic, J., Radulovic, M. et al. Actions of CRF and its analogs. Curr Med Chem 1999, 6: 1035-53.
3. Chang, C.P., Pierce, R.I., O'Connell, S., Rosenfeld, M.G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993, 11: 1187.
4. Chen, R., Lewis, K.A., Perrin, M.H., Vale, W.W. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Proc Natl Acad Sci USA 1993, 90: 8967.
5. Kishimoto, T., Pearse, R.V. II, Lin, C.R., Rosenfeld, M.G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA 1995, 92: 1108-12.
6. Perrin, M., Donaldson, C., Chen, R. et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA 1995, 92: 2969-73.
7. 125I-Antisauvagine-30: A novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. Neuropharmacology 2001, 40: 114-22.
8. Hsu, S.Y., Hsueh, A.J.W. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001, 7: 605-11.
9. Li, C., Vaughan, J., Sawchenko, P.E., Vale, W.W. Urocortin III-immunoreactive projections in rat brain: Partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci 2002, 22: 991-1001.
10. Dautzenberg, F.M., Kilpatrick, G.J., Hauger, R.L., Moreau, J. Molecular biology of the CRH receptors in the mood. Peptides 2001, 22: 753-60.
11. Lovenberg, T.W., Chalmers, D.T., Liu, C., De Souza, E.B. CRF2α and CRF2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995, 136: 4139-42.
12. Vita, N., Laurent, P., Lefort, S. et al. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett 1993, 335: 1-5.
13. Lechner, S.M., Valentino, R.J. Glucocorticoid receptor-immunoreactivity in corticotrophin-releasing factor afferents to the locus coeruleus. Brain Res 1999, 816: 17-28.
14. Deak, T., Nguyen, K.T., Ehrlich, A.L. et al. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999, 140: 79-86.
15. Habib, K.E., Weld, K.P., Rice, K.C. et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 2000, 97: 6079-84.
16. Heinrichs, S.C., Lapsansky, J., Lovenberg, T.W., De Souza, E.B., Chalmers, D.T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept 1997, 71: 15-21.
17. Curtis, A.L., Grigoriadis, D.E., Page, M.E., Rivier, J., Valentino, R,J. Pharmacological comparison of two corticotropin-releasing factor antagonists: In vivo and in vitro studies. J Pharmacol Exp Ther 1994, 268: 359-65.
18. Adinoff, B., Anton, R., Linnoila, M., Guidotti, A., Nemeroff, C.B., Bissette, G. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmocology 1996, 15: 288-95.
19. Rodriguez de Fonseca, F., Carrera, M.R.A., Navarro, M., Koob, G.F., Weiss, F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276: 2050-4.
20. De Vries, A.C., Pert, A. Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotrophin-releasing factor. Psychopharmacology 1998, 137: 333-40.
21. Koob, G.F., Weiss, F. Neuropharmacology of cocaine and ethanol dependence. Recent Dev Alcohol 1992, 10: 201-33.
22. Menzaghi, F., Rassnick, S., Heinrichs, S. et al. The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann NY Acad Sci 1994, 739: 176-84.
23. Pich, E.M., Lorang, M., Yeganeh, M. et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995, 15: 5439-47.
24. Zoltan, S. Neurobiology of stress and cocaine addiction: Studies on corticotrophin-releasing factor in rats, monkeys and humans. Ann NY Acad Sci 1997, 66: 371-87.
25. Zobel, A.W., Nickel, T., Kunzel, H.E. et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 2000, 34: 171-81.
26. O'Toole, S.M., Sekula, L.K., Rubin, R.T. Pituitary-adrenal cortical axis measures as predictors of sustained remission in major depression. Biol Psychiatry 1997, 42: 85-9.
27. Duclos, M., Corcuff, J.B., Roger, P., Tabarin, A. The dexamethasone-suppressed corticotrophin-releasing hormone stimulation test in anorexia. Clin Endocrinol 1999, 51: 725-31.
28. Licinio, J., Wong, M.L., Gold, P.W. The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Psychiatry Res 1996, 2: 75-83.
29. Hotta, M., Shibasaki, T., Masuda, A. et al. The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. J Clin Endocrinol Metab 1986, 62: 319-24.
30. Smith, S.R., de Jonge, L., Pellymounter, M. et al. Peripheral administration of human corticotropin-releasing hormone: A novel method to increase energy expenditure and fat oxidation in man. J Clin Endocrinol Metab 2001, 86: 1991-8.
31. Schwartz, M.W., Seeley, R.J., Campfield, L.A., Burn, P., Baskin, D.G. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996, 98: 1101-6.
32. Richard, D., Huang, Q., Timofeeva, E. The corticotropin-releasing hormone system in the regulation of energy balance in obesity. Int J Obes Relat Metab Disord 2000, 24(Suppl 2): S36-9.
33. Richard, D. Exercise and the neurobiological control of food intake and energy expenditure. Int J Obes Relat Metab Disord 1995, 19 (Suppl 4): S73-9.
34. Webster, E.L., De Souza, E.B. Corticotropin-releasing factor regulation by divalen cations and guanine nucleotides. Endocrinology 1988, 122: 609-17.
35. Webster, E.L., Lewis, D.B., Torpy, D.J., Zachman, E.K., Rice, K.C., Chrousos, G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996, 137: 5747-50.
36. Schulz, D.W., Mansbach, R.S., Sprouse, J. et al. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 1996, 93: 10477-82.
37. Hsin, L.W., Webster, E.L., Chrousos, G.P. et al. Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: The development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor. Bioorg Med Chem Lett 2000, 10: P707.10.
38. Hsin, L.W., Tian, X., Webster, E.L. et al. CRHR1 receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. Bioorg Med Chem 2002, 10: 175-83.
39. Tian, X., Hsin, L.W., Webster, E.L. et al. The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type. Bioorg Med Chem Lett 2001, 11: 331-3.